Valuation
- Market cap
- 6,474,000
- Revenue TTM
- $0
- Net income TTM
- $-13,650,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- 0.00
Trading
- Volume
- 23,600
- Avg volume
- 52,586
- Day's range
- $1.22 – $1.29
- Shares out
- 5,179,000
- Stochastic %K
- 13%
- Beta
- —
- Analysts
- Strong Buy
- Price target
- $10.00
Company profile
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment...
Show more
Regentis Biomaterials Ltd., a regenerative medicine company, develops and commercializes tissue repair solutions in the United States. It offers Gelrin, a platform based on hydrogel matrix of polyethylene glycol diacrylate and denatured fibrinogen for the treatment and regeneration of damaged or diseased tissue; and GelrinC, a cell-free and off-the-shelf hydrogel, which is in Phase II clinical trial for the treatment of cartilage injuries in the knee. The company was incorporated in 2004 and is based in Herzliya, Israel.
- Industry
- Medical Instruments & Supplies
- Sector
- Healthcare
- Phone
- 972 9 960 1917
- Website
- https://www.regentis.co.il
- Address
- 60, Medinat Hayehudim, Entrance C Herzlia Pituach, Herzliya, Israel
Latest news
No headlines yet.
